Meaningful Clinical Endpoints with ERG

Mitchell Brigell occupies the position of Head-Clinical Development & Strategy at Ocuphire Pharma, Inc. Additionally, he formerly held the position of Vice President-Clinical Development at Aerpio Therapeutics, Inc. as well as Executive Director of Translational Medicine, Ophthalmology at Novartis Institutes of BioMedical Research. He also held roles of increasing responsibility at Parke-Davis/Pfizer in Experimental Medicine and Clinical Technologies. He originally joined the pharmaceutical industry as part of the Clinical Development team for Pregabalin (Lyrica). Dr. Brigell spent over a decade in academic medicine at Loyola University and the University of Chicago in the Departments of Neurology, Neuroscience, and Ophthalmology. His area of academic interest focused on electrophysiological and behavioral effects of diseases of the retina and optic nerve. He has published over 70 scientific papers, is a Fellow of the Association of Research in Vision and Ophthalmology, and is the Vice-President of the Americas for the International Society for Clinical Electrophysiology of Vision. Dr. Brigell is on the Editorial Board of Translational Vision Science and Technology and Documenta Ophthalmologica. Dr. Brigell received his Ph.D. in physiological psychology from Kansas State University and did his post-doctoral research in visual electrophysiology at Northeastern University, under the guidance of John Armington.